Acumen Pharmaceuticals

What Acumen Pharmaceuticals does

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted immunotherapies for Alzheimer's disease and related neurodegenerative conditions. The company's lead candidate, sabirnetug (ACU193), is a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs), which the company identifies as early and persistent drivers of Alzheimer's-associated pathology. Sabirnetug is being evaluated in the ongoing Phase 2 ALTITUDE-AD trial, a global, randomized, double-blind, placebo-controlled study enrolling 542 patients with early Alzheimer's disease across sites in the United States, Canada, the European Union, and the United Kingdom, with topline results expected in late 2026. A completed Phase 1 INTERCEPT-AD study showed rapid, dose-proportional target engagement, statistically significant amyloid plaque reduction in higher-dose cohorts, and an ARIA-E rate of 10.4%, which Acumen positions as a differentiated safety profile versus other anti-amyloid antibodies. The company is also developing a subcutaneous formulation of sabirnetug and an Enhanced Brain Delivery program (ACU301, ACU401) that combines Acumen's AβO-selective antibodies with JCR Pharmaceuticals' J-Brain Cargo blood-brain barrier penetration technology, which has demonstrated 14-40x higher brain antibody levels in non-human primates. Acumen is publicly traded on NASDAQ under the ticker ABOS, is headquartered in Newton, Massachusetts, and is governed under Virginia law. As a pre-revenue biotech, the company is funded through equity offerings (a $130 million public offering in July 2023 and a $35.75 million private placement in March 2026) and a $50 million senior secured loan facility from K2 HealthVentures, with $116.9 million in cash, cash equivalents, and marketable securities as of December 31, 2025, expected to fund operations into early 2027.

Name

Acumen Pharmaceuticals

Legal name

Acumen Pharmaceuticals, Inc.

Website

https://acumenpharm.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

51–100 employees

Short description

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing sabirnetug (ACU193), a monoclonal antibody selectively targeting toxic amyloid beta oligomers for early Alzheimer's disease, currently in a 542-patient Phase 2 trial with topline results expected late 2026.

Ownership category

akta.pro rank

Product category

Alzheimer's Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Lead Optimization & Preclinical Candidate Selection (HLAIALAB), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Alzheimer's therapeutics
• Monoclonal antibody drugs
• Neurodegenerative treatments
• Clinical-stage biopharmaceutical
• Amyloid beta oligomers

Headquarters

HQ city

Carmel

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biopharmaceutical company. Once sabirnetug (ACU193) receives regulatory approval, the company plans to commercialize its therapeutic candidates for Alzheimer's disease treatment. Revenue will come from product sales following FDA approval and commercial launch.
2. Milestone Payments from Licensing: JCR Pharmaceuticals is eligible to receive up to USD 555 million in option, development, and sales milestone payments from Acumen's Enhanced Brain Delivery program, plus tiered royalties on net sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Acumen Pharmaceuticals is developing sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer's disease. The lead candidate is in Phase 2 ALTITUDE-AD clinical trials, with a parallel Enhanced Brain Delivery (EBD) program combining AβO-selective antibodies with JCR Pharmaceuticals' J-Brain Cargo blood-brain barrier penetration technology. The company is a pre-revenue clinical-stage biopharmaceutical company targeting FDA approval for disease-modifying Alzheimer's treatments.

Product overview

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted Alzheimer's disease treatments. The company's lead product is sabirnetug (ACU193), a monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs). Sabirnetug is currently in Phase 2 clinical trials (ALTITUDE-AD) following successful completion of Phase 1 (INTERCEPT-AD). The company is also advancing an Enhanced Brain Delivery program with development candidates ACU301 and ACU401, which combine AβO-selective antibody expertise with JCR Pharmaceuticals' J-Brain Cargo technology to improve brain penetration. The pipeline includes both intravenous and subcutaneous formulations of sabirnetug.

Differentiator

Problem solved

Functional benefit

Products and services

• Sabirnetug (ACU193) A humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer's disease. Designed to prevent AβOs from binding to dendritic spines and preserve neuronal function, with disease-modifying benefits and an improved safety profile (10.4% ARIA-E rate). Currently in Phase 2 clinical trials with both intravenous and subcutaneous formulations in development.
• Enhanced Brain Delivery (EBD) Program Development program combining Acumen's AβO-selective antibody expertise with JCR Pharmaceuticals' J-Brain Cargo blood-brain barrier penetrating technology to achieve 14-40x higher brain penetration in non-human primates compared to native antibodies, for improved Alzheimer's disease treatment delivery to the brain.
• ACU301 Preclinical development candidate in the Enhanced Brain Delivery program for Alzheimer's disease, combining AβO-selective antibody with J-Brain Cargo technology for enhanced brain penetration and improved therapeutic delivery across the blood-brain barrier.
• ACU401 Preclinical development candidate in the Enhanced Brain Delivery program for Alzheimer's disease, combining AβO-selective antibody with J-Brain Cargo technology for enhanced brain penetration and improved therapeutic delivery across the blood-brain barrier.

Quantifiable outcome

• 14-40x higher brain levels in non-human primates compared to native antibodies with EBD candidates
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• JCR PharmaceuticalscoreTechnology or Integration · 17 June 2026Acumen Pharmaceuticals exercised its exclusive option to develop up to two therapeutic candidates for Alzheimer's disease using JCR Pharmaceuticals' proprietary J-Brain Cargo blood-brain barrier-penetrating technology platform. JCR is eligible to receive up to USD 555 million in option, development, and sales milestone payments, with Acumen targeting IND filing in mid-2027. The collaboration combines Acumen's AβO-selective antibody expertise with JCR's BBB technology to deliver biologics across the blood-brain barrier.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Eli Lilly and Company: Eli Lilly markets Kisunla (donanemab), an FDA-approved anti-amyloid antibody for early Alzheimer's disease. Directly competes with sabirnetug in the same indication with similar mechanism but established commercial position, making it the most relevant large-cap benchmark.
• Eisai Co., Ltd. Eisai co-developed and markets Leqembi (lecanemab) with Biogen — the leading FDA-approved anti-amyloid antibody for Alzheimer's. Represents the most relevant commercial benchmark and competitive threat to sabirnetug.
• Biogen Inc. Biogen developed Aduhelm (aducanumab) and co-markets Leqembi (lecanemab) with Eisai for Alzheimer's disease. A direct CNS specialty pharma peer with both approved products and an active pipeline targeting neurodegenerative disease.
• Roche Holding AG: Roche developed gantenerumab, an anti-amyloid antibody that failed Phase 3 trials for Alzheimer's, illustrating the binary risk profile comparable to Acumen's sabirnetug. A broad incumbent in CNS drug development with comparable scientific ambitions.
• Sage Therapeutics: Sage Therapeutics is a CNS-focused biopharma developing treatments for brain disorders, recently acquired by and operating within Biogen. Comparable as a CNS-specialized biotech with branded neuroscience therapeutics targeting CNS indications.

Direct peers

• Prothena Corporation: Prothena is a clinical-stage biotech developing anti-amyloid antibody therapeutics for Alzheimer's disease, including tau and amyloid-beta targeted programs. Directly comparable as a focused neuroscience biotech developing disease-modifying antibodies in the same indication.
• Cassava Sciences: Cassava Sciences is a clinical-stage biotech developing simufilam for Alzheimer's disease. Comparable as a small public CNS-focused single-asset biotech navigating Phase 2/3 development in the same therapeutic space.
• Denali Therapeutics: Denali Therapeutics develops therapeutics for neurodegenerative diseases with proprietary blood-brain barrier delivery technology (similar to JCR's J-Brain Cargo used by Acumen). Highly relevant peer given overlapping BBB delivery approach and CNS pipeline.
• Anavex Life Sciences: Anavex Life Sciences is a clinical-stage biotech developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. Comparable as a small public CNS biotech with late-stage clinical assets in Alzheimer's.

Emerging players

• Cogstate Ltd: Cogstate provides cognitive assessment technology widely used in Alzheimer's clinical trials, including as outcomes tools in programs like ALTITUDE-AD. Relevant as an adjacent participant in the Alzheimer's clinical research ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/acumenpharm
• LinkedInlinkedin.com/company/acumen-pharm
• Instagraminstagram.com/acumenpharm

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds8 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acumen Pharmaceuticals